0.89
+0.015(+1.72%)
Currency In USD
Address
350 Fifth Avenue
New York City, NY 10118
United States of America
Phone
431 890 6360
Sector
Healthcare
Industry
Biotechnology
Employees
82
First IPO Date
April 18, 2019
| Name | Title | Pay | Year Born |
| Dr. Malte Peters M.D. | Chief Executive Officer, President & Director | 938,285 | 1962 |
| Ms. Mary Theresa Coelho M.B.A. | Executive Vice President, Chief Financial Officer & Director | 603,121 | 1962 |
| Dr. Mark Winderlich Ph.D. | Chief Research & Development Officer | 0 | 1986 |
| Dr. Klaus Orlinger Ph.D. | Chief Scientific Officer | 0 | 1978 |
| Dr. Daniel D. Pinschewer M.D. | Co-Founder & Member of Scientific Advisory Board | 0 | 1975 |
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company's preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer. HOOKIPA Pharma Inc. has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. The company was incorporated in 2011 and is headquartered in New York, New York.
